2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 833

A Small Proportion of Patients with Systemic Sclerosis with Suspected Pulmonary Hypertension Meet the Published Inclusion/Exclusion Criteria for Two Systemic Sclerosis Associated Pulmonary Arterial Hypertension Screening Algorithms– Results from a Single Center Cohort
Abstract Number: 328

A Study of Serum Electrolyte Levels after Denosumab Administration
Abstract Number: 230

A Survey of Knowledge of Optimal Gout Management in an Academic Primary Care Setting
Abstract Number: 2979

a Systematic Literature Review on the Treatment of Skin, Mucosa and Joint Involvement of BehçEt’s Syndrome Informing the Eular Recommendations for the Management of BehçEt’s Syndrome
Abstract Number: 610

A Systematic Review and Meta-Analysis of Comparative Efficacy of Biologics in Treating Patients with Rheumatoid Arthritis: Assessment of Long-Term Radiographic Progression from Published Clinical Trials
Abstract Number: 293

A Systematic Review and Network Meta-Analysis of Long-Term Trials of Pharmacological Treatments in Knee Osteoarthritis
Abstract Number: 368

A Systematic Review of Chronic Pain Assessments with Children and Young People: Exploring Administrative, Scoring and Classification Issues
Abstract Number: 1222

A Systematic Review of Consumer Perceived Health Service Needs Related to Osteoarthritis
Abstract Number: 1063

A Systematic Review of Direct Oral Anticoagulant Use in Antiphospholipid Syndrome
Abstract Number: 1169

A Systematic Review of Rheumatic Disease Epidemiology in the Indigenous Populations of Canada, the United States, Australia and New Zealand
Abstract Number: 91

A Systematic Review of Smartphone Applications for Measuring and Recording Rheumatoid Arthritis Disease Activity
Abstract Number: 56

A Systems Biology Approach to Investigating Beneficial Effects of Endurance Exercise in Myositis Patients
Abstract Number: 1443

A Therapeutic Peptide Vaccine Reduces Pro-Inflammatory Responses and Suppresses Arthritis in the Cartilage Proteoglycan G1 Domain-Induced Mouse Model of Rheumatoid Arthritis
Abstract Number: 940

A Trial of XmAb®5871, a Reversible Inhibitor of CD19+ Cells, in IgG4-Related Disease
Abstract Number: 2087

A Type I Interferon Signature in Monocytes and Decreased Levels of Circulating Plasmacytoid Dendritic Cells in Patients with Primary Antiphospholipid Syndrome

« Previous Page
1
…
6
7
8
9
10
…
219
Next Page »

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].